Peptides without rules: the Kennedy administration's shortcut

What The Washington Post reported

On 7 October 2026, The Washington Post reported as an exclusive that the Trump administration is crafting plans to allow «the temporary sale of some previously restricted peptides» while it writes new regulations, according to two people familiar with the matter¹. The story, by Rachel Roubein, is paywalled; what follows comes from the text the paper itself posted on social media and from those who summarized it¹²³.

Precision matters here: this is a press report, not an official decision. The Alliance for Pharmacy Compounding (APC), which wants the change, says it plainly: the plan has not been announced, has no timeline and could change³. As of 12 October 2026, FDA had issued no press announcement on peptides, and its official 503A list page was still dated 14 May¹⁰¹¹. Which peptides would be covered is also unknown³.

Why a shortcut

In April 2026 FDA removed 12 peptides from «Category 2» (significant safety risks) because their nominations were withdrawn, but that did not put them on the 503A list or in Category 1; they were left in a gray area⁶. In July, its Pharmacy Compounding Advisory Committee (PCAC) voted for 6 of 7 peptides against the agency staff's written recommendation; none has been added to the list and the recommendation is not binding⁴. We cover those votes in another article.

The obstacle is the calendar. For a compounding pharmacy to legally use these bulk substances, FDA must add them to the 503A list through notice-and-comment rulemaking⁴⁷. NPR reported that the process could stretch into 2027 or 2028 and that Kennedy could possibly invoke special authority to make them available sooner⁵. The October report indicates that such a fast track is being prepared¹².

How it would work: «enforcement discretion»

The Post did not detail the mechanism, based on what has been published of the story. Biologist Paul Knoepfler, who summarized it on his blog, describes it as «something like FDA enforcement discretion»; that is his interpretation, not a quote from the paper². The tool already exists: FDA's «Category 1» is an interim policy under which, per law firm Orrick's analysis, the agency permits compounding of nominated substances with no significant safety risks identified⁶. It is not an approval and does not change the law: it is a decision not to enforce in the meantime.

It is almost word for word what the compounding industry asked for. APC reported meeting FDA twice to request interim enforcement discretion for state-licensed pharmacies, conditioned on enhanced patient disclosures, serious adverse-event reporting and data collection on use³.

It also has a legal flank: according to law firm Mintz, market demand is not among the regulatory criteria for the 503A list, and both listing and a Category 1 classification could be challenged under the Administrative Procedure Act⁷.

The politics behind the plan

The most striking detail is political. According to the Post story as quoted by Knoepfler, the American Academy of Peptide Medicine sought polling on the issue this summer and «tapped a firm run by Trump's pollster, Tony Fabrizio»; a polling memo viewed by the paper cites a «political upside» to expanding access². We have not found the poll's results published².

Health Secretary Robert F. Kennedy Jr. makes no secret of his position. On Joe Rogan's podcast he said «I'm a big fan of peptides» and that he has used them himself for a couple of injuries⁹. Before the July vote, eight new committee members were appointed; according to NPR, most have ties to the peptide industry and almost always voted in favor⁵. HHS replied that all went through the standard ethics and vetting process⁵, and FDA told Knoepfler that no conflict-of-interest waivers were issued for those meetings².

What FDA's scientists said

Agency scientists advised the panel to vote no on all seven peptides⁴⁵. In some cases they could not find any published clinical studies in humans, and they cited risks such as the potential to encourage cancer growth or to trigger a massive immune response⁵. FDA official Russell Wesdyk described a problem that comes before efficacy: products with the same name varied widely in chemical composition, and without knowing exactly what each one is, quality standards cannot be set⁵.

ProPublica reported in April that three former FDA officials closely familiar with the criteria used to assess these peptides say Kennedy has mischaracterized their work: the 2023 decision was supported by numerous documented safety concerns⁸. Peter Lurie, a former FDA official who now leads the Center for Science in the Public Interest, warned: «The Wild West is about to become wilder», and Eric Topol of Scripps Research said these peptides have no data to support their safety and efficacy⁹.

Meanwhile, sport is tightening

The opposite direction comes from anti-doping. According to USADA, the 2027 Prohibited List, effective 1 January 2027, now names «peptides» in general as prohibited substances in class S0, with BPC-157 and TB-500 among the examples; S0 substances are prohibited at all times¹². Washington would be opening the door just as sport closes it.

What it means for aesthetic and wellness clinics

Clinics are already part of the channel: ProPublica described wellness spas, multilevel marketers and telehealth sites selling «research grade» peptides labeled not for human use⁸. One of the new committee members, Asare Christian, runs a Pennsylvania clinic that advertises peptide protocols and hormone optimization⁵. NPR added a key detail: if FDA reclassifies these peptides, clinicians could prescribe them outside the narrow indications the committee reviewed, such as BPC-157 for ulcerative colitis⁵.

• Tolerating is not approving. The 503A list is not an FDA approval and lacks controls such as detailed prescribing information and the promotion restrictions of approved drugs⁷; temporary discretion would be even less.
• Watch the marketing. Mintz warned that telehealth platforms, med spas and wellness clinics will need to be careful with claims, especially disease-related ones, and that «clinically proven» would lack support⁷.
• States still rule. State boards of pharmacy and medicine remain the primary regulators of 503A pharmacies, whatever FDA does⁷.
• «Research use only» is not included. What APC requested concerns state-licensed compounding pharmacies, not vials sold online³.

On KPV and skin, the published evidence is preclinical. KPV, the Lys-Pro-Val tripeptide of α-MSH, has been studied in human keratinocytes¹⁵; in 2025 it was observed to reduce particulate-induced IL-1β and cell death in keratinocytes and a 3D skin model, and the authors proposed uses in functional cosmetics¹³. A review by Münster dermatologists proposed KPV and derivatives as future candidates for skin wounds, with anti-inflammatory effects but without α-MSH's pigmentation¹⁴. Our PubMed search found no clinical trials of KPV on human skin.

For physicians in Panama and the region, none of this changes local regulation: an FDA decision, let alone a report about a future one, is not a health registration in another country.